产品
编 号：F761469
分子式：C19H21N3O6S2
分子量：451.52
分子式：C19H21N3O6S2
分子量：451.52
产品类型
规格
价格
是否有货
结构图
CAS No: 920459-41-2
产品详情
生物活性：
DprE1-IN-1 is a potent, orally active DprE1 inhibitor with favorable hepatocyte stability, low cytotoxicity and low hERG channel inhibition. DprE1-IN-1 displays potent activity against both agent-susceptible and clinically isolated drug-resistant Tuberculosis strains with MICs10 CFU reduction in macrophages.
体内研究：
DprE1-IN-1 (100 mg/kg; oral gavage; 5 days per week from day 10 until day 30) can reduce the bacterial burden in the lungs by 0.54 log10 CFU after three weeks of treatment in M. tuberculosis H37Rv infected mice.Animal Model:Female SPF Balb/c mice (18-20 g) (M. tuberculosis H37Rv infected)
Dosage:100 mg/kg
Administration:Oral gavage; 5 days per week from day 10 until day 30
Result:Reduced the bacterial burden in the lungs by 0.54 log10 CFU compared with the untreated control group after three weeks of treatment.
体外研究：
DprE1-IN-1 (compound 17b) (64 to 0.26 μg/mL; 48 hours) has high safety with low cytotoxicity towards HepG2, J774A.1 macrophage cells (IC50>60 μg/mL) and Vero (IC50=58.18 μg/mL) alongside potent efficacy and good druggability.DprE1-IN-1 can reduce 1.19 and 1.29 log10 CFU M. tuberculosis in J774A.1 macrophages at 5 μg/mL and 10 μg/mL, respectively, for 3 days treatment.DprE1-IN-1 (compound 17b) (1 μM; 0-120 minutes) has high stability in human and mice hepatocytes (remaining of 42% and 49.7%, respectively; t1/2 of 24.0 and 29.7 min, respectively).
DprE1-IN-1 is a potent, orally active DprE1 inhibitor with favorable hepatocyte stability, low cytotoxicity and low hERG channel inhibition. DprE1-IN-1 displays potent activity against both agent-susceptible and clinically isolated drug-resistant Tuberculosis strains with MICs10 CFU reduction in macrophages.
体内研究：
DprE1-IN-1 (100 mg/kg; oral gavage; 5 days per week from day 10 until day 30) can reduce the bacterial burden in the lungs by 0.54 log10 CFU after three weeks of treatment in M. tuberculosis H37Rv infected mice.Animal Model:Female SPF Balb/c mice (18-20 g) (M. tuberculosis H37Rv infected)
Dosage:100 mg/kg
Administration:Oral gavage; 5 days per week from day 10 until day 30
Result:Reduced the bacterial burden in the lungs by 0.54 log10 CFU compared with the untreated control group after three weeks of treatment.
体外研究：
DprE1-IN-1 (compound 17b) (64 to 0.26 μg/mL; 48 hours) has high safety with low cytotoxicity towards HepG2, J774A.1 macrophage cells (IC50>60 μg/mL) and Vero (IC50=58.18 μg/mL) alongside potent efficacy and good druggability.DprE1-IN-1 can reduce 1.19 and 1.29 log10 CFU M. tuberculosis in J774A.1 macrophages at 5 μg/mL and 10 μg/mL, respectively, for 3 days treatment.DprE1-IN-1 (compound 17b) (1 μM; 0-120 minutes) has high stability in human and mice hepatocytes (remaining of 42% and 49.7%, respectively; t1/2 of 24.0 and 29.7 min, respectively).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备